Skip to content

A clinical trial to study the effects of parathyroidectomy and a drug called cinacalcet on bone biopsy indices

Bone Indices before and after parathyroidectomy or cinacalcet therapy in patients with renal hyperparathyroidism: A randomized controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/03/040787
Enrollment
20
Registered
2022-03-03
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N186- End stage renal disease Health Condition 2: O- Medical and Surgical

Interventions

Intervention1: Parathyroidectomy: Bone biopsy will be performed intraoperatively during curative parathyroidectomy and also 3 to 12 months after the surgery. Control Intervention1: Cinacalcet: Dose -

Sponsors

PGIMER Chandigarh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with Refractory sHPT defined as following: 1) Serum iPTH level greater than 800 pg/mL on two or more occasions after optimal drug therapy and/or 2)Radioisotope scan or Ultrasound imaging shows parathyroid diffuse or nodular hyperplasia or Tertiary Hyperparathyroidism One serum calcium determination obtained from the central laboratory must be greater than 8.4 mg/dL One Bone Alkaline Phosphatase (BALP) determination obtained from the central laboratory must be greater than 20.9 ng/mL. ESRD patients on maintainence haemodialysis

Exclusion criteria

Exclusion criteria: - Any chronic disease that may affect bone health significantly(eg :Cushings disease,Addisons disease ,Severe liver disease like biliary cirrhosis) - Pregnancy or lactation(post menopausal females) - Had a parathyroidectomy in the 3 months, before the date of informed consent - Ever received therapy with cinacalcet in cinacalcet arm - Prior use of Bisphosphonates in last 5 years or Denosumab in last 1 year - History of steroid intake(Prednisolone 5mg or equivalent for greater than 3 months in last 1 year)

Design outcomes

Primary

MeasureTime frame
To compare the change in Bone Formation Rate(BFR) from baseline to end of the study. Change From Baseline to End of Study in Osteoclast Perimeter (Osteoclast Perimeter/Eroded Perimeter)Timepoint: 1 year

Secondary

MeasureTime frame
Change From Baseline to End of Study in Fibrosis Area/Tissue AreaTimepoint: 1 year;Change in CT -CAC score from baseline to the end of the studyTimepoint: 1 year;To compare the change in bone micro architecture & BMD from before and after parathyroidectomy/cinacalcet therapy. Timepoint: 1 year;To compare the various biochemical and bone turnover markers from before and after parathyroidectomy/cinacalcet therapy.Timepoint: 1 year

Countries

India

Contacts

Public ContactDrAnirudh J Shetty

Post Graduate Institute of Medical Education and Research

bhadadask@gmail.com9876602448

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026